| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500659 | Farmacia Hospitalaria | 2006 | 7 Pages |
Abstract
A high variability is observed in the use of rasburicase in our patients. The hematology and pharmacy services have been working jointly to prepare a consensus-based protocol according to which, depending on the patient's risk of developing TLS (tumoral lysis syndrome), standard prophylaxis is administered to low-risk patients (intravenous hydration, alopurinol and urine alcalinization) and rasburicase is administered initially for 1-3 days to patients with high risk of developing TLS.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
F. Llinares, A. Burgos, P. Fernández, B. Villarrubia, P. Ferrandis, J.P. Ordovás,